SAN FRANCISCO, Oct. 27, 2023 (GLOBE NEWSWIRE) — Hagens Berman urges Outset Medical, Inc. (NASDAQ: OM) investors who suffered substantial losses to submit your losses now. The investigation focuses on the propriety of Outset Medical’s disclosures concerning marketing authorizations and commercialization of its flagship dialysis device, the Tablo Hemodialysis System…Read More
Hagens Berman Encourages Outset Medical OM Shareholders with Losses to Contact its Attorneys Firm Investigating Possible Securities Law Violations
